Results 191 to 200 of about 5,019 (231)

Bispecific T-cell engager therapy for multiple myeloma

Best Practice & Research Clinical Haematology
With upfront use of triplet- and quadruplet-based regimens coupled with autologous stem cell transplant (ASCT) and maintenance lenalidomide, a high proportion of multiple myeloma (MM) patients are achieving deep and durable responses. Yet, myeloma invariably relapses, with refractoriness to one or more drugs at first relapse.
Diana Cirstea, Benjamin Puliafito, Bridget E. Kim, Matt Lei, Noopur Raje   +4 more
openaire   +2 more sources

Perils and Problems in Bispecific T-Cell Engager Antibodies

Current Drug Safety
: Bispecific antibodies (BsAbs) are promising immunotherapies for cancer treatment designed to engage both tumour and immune cells. However, their use is associated with potential toxicities, including cytokine release syndrome (CRS), neurotoxicity, and on-target, off-tumour toxicity.
Bisht, Khushboo, Joshi Rajat, Kumar
exaly   +3 more sources

Bispecific T-cell engager therapy for gastrointestinal cancers

Cancer Letters
Though cancer immunotherapy has revolutionized the treatment of several tumor types, progress for immunotherapy in gastrointestinal (GI) tumors has been difficult. Recently, there have been rapid developments in bispecific T-cell engagers for the treatment of several hematologic malignancies.
Kyle A. Burton, Anastasia E. Metropulos, Suneel D. Kamath, Hidayatullah G. Munshi, Daniel R. Principe   +4 more
openaire   +2 more sources

Clinical Experience with Bispecific T Cell Engagers

2019
Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested in relapsed and refractory (R/R) non-Hodgkin's Lymphoma (NHL), R/R acute lymphoblastic leukemia ...
openaire   +2 more sources

Bispecific T Cell Engager for Cancer Therapy

2011
Treatment with monoclonal antibodies of the human IgG1 and IgG2 isotypes have become a mainstay in cancer therapy, particularly, in hematological malignancies (Ball and Broome 2010). Engagement of Fcγ receptor-bearing immune effector cells, complement fixation, induction of apoptosis, and neutralization of growth factors are major modes of action of ...
Patrick A. Baeuerle, Gerhard Zugmaier, Dominik Rüttinger   +2 more
openaire   +1 more source

PSMA-targeted bispecific Fab conjugates that engage T cells

Bioorganic & Medicinal Chemistry Letters, 2017
Bioconjugate formats provide alternative strategies for antigen targeting with bispecific antibodies. Here, PSMA-targeted Fab conjugates were generated using different bispecific formats. Interchain disulfide bridging of an αCD3 Fab enabled installation of either the PSMA-targeting small molecule DUPA (SynFab) or the attachment of an αPSMA Fab (BisFab)
James T, Patterson, Jason, Isaacson, Lisa, Kerwin, Ghazi, Atassi, Rohit, Duggal, Damien, Bresson, Tong, Zhu, Heyue, Zhou, Yanwen, Fu, Gunnar F, Kaufmann   +9 more
openaire   +2 more sources

Bispecific antibodies for polyclonal T-cell engagement.

Current opinion in molecular therapeutics, 2003
Single-chain bispecific antibodies are emerging as an extremely powerful and promising class of polyclonal T-cell-engaging proteins with hitherto unknown properties. Such bispecific antibodies have the potential to bypass most T-cell escape mechanisms selected in tumor cells during their development into solid tumors and metastases.
Patrick A, Baeuerle, Peter, Kufer, Ralf, Lutterbüse   +2 more
openaire   +1 more source

Bispecific T-Cell Engagers (BiTEs) in Immunotherapy

Bispecific T-cell engagers (BiTEs) is a novel subclass of T-cell-engaging bispecific antibodies (bulbs) that are promising for the treatment of cancer. BiTEs direct cytotoxic T-cell activity towards malignant cells, resulting in targeted destruction of tumor cells. This chapter provides an overview of the current landscape of BiTE therapy, highlighting
Mohsen Sheykhhasan, Anita S. La'ah, Amirhossein Ahmadieh-Yazdi, Hamid Tanzadehpanah, Hanie Mahaki, Hamed Manoochehri, Piao Yang, Naresh Poondla, Naser Kalhor, Sharafaldin Al-Musawi   +9 more
openaire   +1 more source

Bispecific T cell engager therapy for refractory rheumatoid arthritis

Nature Medicine
Bispecific T cell engagers (BiTEs) kill B cells by engaging T cells. BiTEs are highly effective in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use.
Laura Bucci, Melanie Hagen, Tobias Rothe, Maria Gabriella Raimondo, Filippo Fagni, Carlo Tur, Andreas Wirsching, Jochen Wacker, Artur Wilhelm, Jean-Philippe Auger, Milena Pachowsky, Markus Eckstein, Stefano Alivernini, Angelo Zoli, Gerhard Krönke, Stefan Uderhardt, Aline Bozec, Maria-Antonietta D’Agostino, Georg Schett, Ricardo Grieshaber-Bouyer   +19 more
openaire   +2 more sources

Computational simulations of bispecific T cell engagers by a multiscale model

Biophysical Journal
The use of bispecific antibodies as T cell engagers can bypass the normal T cell receptor-major histocompatibility class interaction, redirect the cytotoxic activity of T cells, and lead to highly efficient tumor cell killing. However, this immunotherapy also causes significant on-target off-tumor toxicologic effects, especially when it is used to ...
Zhaoqian, Su, Steven C, Almo, Yinghao, Wu   +2 more
openaire   +2 more sources